Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472082 · ClinicalTrials.gov registry record · Phase 1
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00472082 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 5 participants.
The verdict
NCT00472082, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in patients with mild impairment of renal function in order to minimize the toxicities of CNI.
Interventions
- DRUG efalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472082
The ClinicalTrials.gov registry entry for NCT00472082 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efalizumab is the first listed.
NCT00472082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472082 about?
NCT00472082 is a clinical study titled "Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients". The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in patients with mild impairment of renal function in order to minimize the tox...
What is the current status of trial NCT00472082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00472082?
The interventions under investigation include: efalizumab (DRUG).
Who is sponsoring clinical trial NCT00472082?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.